BeyondSpring Inc. (BYSI)

US — Healthcare Sector
Peers: INKT  TVRD  ESLA  STRO  CVM  ADAG  OTLK  RLMD  MNOV  CAMP 

Automate Your Wheel Strategy on BYSI

With Tiblio's Option Bot, you can configure your own wheel strategy including BYSI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol BYSI
  • Rev/Share -0.0233
  • Book/Share -0.4352
  • PB -2.7691
  • Debt/Equity -0.0158
  • CurrentRatio 2.1919
  • ROIC -0.2396

 

  • MktCap 83705697.0
  • FreeCF/Share -0.6577
  • PFCF -3.1569
  • PE 41.218
  • Debt/Assets 0.0154
  • DivYield 0
  • ROE -0.0653

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

BeyondSpring Inc. (BYSI) 2025 Annual Shareholders Meeting (Transcript)
BYSI
Published: September 15, 2025 by: Seeking Alpha
Sentiment: Neutral

BeyondSpring Inc. (NASDAQ:BYSI ) 2025 Annual Shareholders Meeting Call September 15, 2025 9:00 AM EDT Company Participants Lan Huang - Co-Founder, Chairman & CEO Presentation Unknown Attendee Good morning, and welcome to the 2025 Annual Meeting of Shareholders of BeyondSpring Inc. Lan Huang Co-Founder, Chairman & CEO Good morning. I'm Lan Huang, Chair of Board of Directors and Chief Executive Officer of BeyondSpring Inc. It's my great pleasure to preside over our company's 2025 Annual Meeting.

Read More
image for news BeyondSpring Inc. (BYSI) 2025 Annual Shareholders Meeting (Transcript)
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting
BYSI
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral

FLORHAM PARK, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it presented interim phase 2 data on the 303 Study, a study in 2L/3L non-small cell lung cancer (NSCLC) after disease progression on 1L PD-1/L1 inhibitors with and without chemotherapy (NCT05599789), with financial support from Merck's (Rahway, NJ USA) Investigator Studies Program and provision of study drug, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, on May 31st, 2025 in Chicago, IL.

Read More
image for news BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting

About BeyondSpring Inc. (BYSI)

  • IPO Date 2017-03-09
  • Website https://www.beyondspringpharma.com
  • Industry Biotechnology
  • CEO Lan Huang
  • Employees 40
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.